Stockholders Approve Reverse Stock Split to Address Nasdaq Compliance
BKYI sits 16% above its 52-week low of $0.49.
Summary
BIO-key stockholders approved a reverse stock split, giving the Board authority to implement it by May 6, 2026, to help regain Nasdaq compliance.
Key Events · Corporate Governance and Compliance · BKYI
-
Reverse Stock Split Approved
Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-10.
-
Board Discretion on Ratio and Timing
The Board of Directors has the authority to determine the exact ratio and timing of the reverse split, to be implemented no later than May 6, 2026.
-
Addresses Nasdaq Non-Compliance
This approval provides a mechanism for the company to potentially regain compliance with Nasdaq's minimum bid price requirement, following a recent non-compliance notice on April 22, 2026.
Analysis · BKYI · Technology
This 8-K reports that BIO-key International's stockholders have approved a reverse stock split, a critical step for the micro-cap company to address its recent Nasdaq non-compliance notice. The Board now has discretion to implement a split ratio between 1-for-2 and 1-for-10 by May 6, 2026. This action is essential for the company to potentially regain compliance with Nasdaq's minimum bid price requirement and avoid delisting, which would severely impact its ability to raise capital and investor confidence. This follows the Nasdaq non-compliance notice issued just two days prior on April 22, 2026.
At the time of this filing, BKYI was trading at $0.57 on NASDAQ in the Technology sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $0.49 to $1.97. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.